Table 3.
MS cases (N = 122) | MS/cannabis (N = 28) | Control (N = 150) | p value | ||
---|---|---|---|---|---|
IL-1 (pg/ml) | 27.6 ± 5.83 | 14.16 ± 3.26 | 4.29 ± 1.13 | <0.001a | <0.001c |
<0.001d | |||||
0.001e | |||||
IL-2 (pg/ml) | 29.77 ± 6.19 | 17.43 ± 4.98 | 5.32 ± 2.28 | <0.001a | <0.001c |
<0.001d | |||||
<0.001e | |||||
IL-4 (pg/ml) | 10.2 ± 3.28 | 13.29 ± 3.79 | 16.88 ± 4.15 | 0.021a | 0.128c |
0.005d | |||||
0.075e | |||||
IL-6 (pg/ml) | 44.85 ± 9.22 | 21.15 ± 5.38 | 9.35 ± 3.29 | <0.001a | <0.001c |
<0.001d | |||||
<0.001e | |||||
IL-10 (pg/ml) | 15.44 ± 3.87 | 27.11 ± 6.49 | 36.59 ± 7.14 | <0.001a | <0.001c |
<0.001d | |||||
<0.001e | |||||
IL-12 (pg/ml) | 96.15 ± 19.37 | 53.88 ± 13.23 | 40.47 ± 10.70 | <0.001a | <0.001c |
<0.001d | |||||
<0.001e | |||||
IL-17 (pg/ml) | 23.74 ± 5.33 | 12.82 ± 3.64 | 3.11 ± 0.75 | <0.001a | <0.001c |
<0.001d | |||||
<0.001e | |||||
IL-22 (pg/ml) | 30.45 ± 7.58 | 22.18 ± 5.87 | 6.17 ± 2.38 | <0.001a | <0.001c |
<0.001d | |||||
<0.001e | |||||
TNF (pg/ml) | 43.63 ± 10.58 | 25.05 ± 7.49 | 12.13 ± 3.97 | <0.001a | <0.001c |
<0.001d | |||||
<0.001e | |||||
IFN-β1 (pg/ml) | 11.42 ± 3.77 | 13.27 ± 3.25 | 14.07 ± 4.19 | 0.094a | 0.238c |
0.054d | |||||
0.126e | |||||
IFN-γ (pg/ml) | 19.27 ± 5.33 | 15.24 ± 4.74 | 8.55 ± 3.19 | 0.005a | 0.048c |
<0.001d | |||||
0.001e |
IL: interleukin; IFN: interferon; TNF: tumor necrosis factor. aOne-way ANOVA test/Kruskal-Wallis test. cComparison between MS cases and MS cases (chronic cannabis users). dComparison between MS cases and controls. eComparison between MS cases (chronic cannabis users) and controls.